MR
Ultragenyx Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DTX301 | Ornithine Transcarbamylase (OTC) Deficiency | Phase 3 |
| UX053 | Glycogen Storage Disease Type III (GSDIII) | Phase 3 |
| UX016 | GNE Myopathy | Phase 1/2 |
| DTX401 | Glycogen Storage Disease Type Ia (GSDIa) | Phase 3 |
| GTX-102 | Angelman Syndrome | Phase 1/2 |
| UX701 | Wilson Disease | Phase 1/2 |
| Crysvita (burosumab) | X-Linked Hypophosphatemia (XLH) | Approved |
| Dojolvi (triheptanoin) | Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | Approved |
Leadership Team at Ultragenyx Pharmaceutical
ED
Emil D. Kakkis
Chief Executive Officer and President
SS
Sharon Shacham
Chief Scientific Officer and Head of R&D
EC
Eric Crombez
Chief Medical Officer
TH
Ted Huizenga
Chief Financial Officer
KP
Karah Parschauer
Chief Legal Officer and Corporate Secretary
JM
John M. Higgins
Chief Business Officer